Genmab — August 2018
-
I videoen, som Peter linkede til i går kl. 20:49, peger Sagar Lonial på Carfilzomib som frontline-mulighed i stedet for bortezomib. Han nævner ikke Ixazomib, som kører adskillige kombistudier med dara for tiden, og som har visse fordele https://www.clinicaltrials.gov/ct2/results?cond=&term=daratumumab+ixazomib&cntry=&state=&city=&dist= http://www.managingmyeloma.com/knowledge-center/faq-library/889-how-should-you-choose-between-carfilzomib-and-ixazomib
-
Sandhedens time: bb2121 head to head mod bl.a. dara https://www.clinicaltrials.gov/ct2/show/NCT03651128?term=daratumumab+ixazomib&rank=6
-
nogen, der kan huske hvorfor vi faldt i juli i år?
-
Har denne været nævnt her? A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind